


FEEVA is a bold new project by the Kirby Institute and the Australian Living Evidence Collaboration.

Working with expert researchers, vaccine developers, regulators, and evidence synthesisers, this project will develop a framework of evidence and consensus based practical tools for the planning and assessment of indirect evidence for vaccines.

www.livingevidence.org.au/research-initiatives/about-feeva



Context


As a scientific community, we have tools for assessing the reliability, usefulness and certainty of data about vaccine effectiveness produced by randomised control trials (RCTs).

However, sometimes it is not feasible to conduct an RCT to test a vaccine, in which case other study types (like animal models, in vitro assays, natural history studies and human challenge studies) can be used to provide indirect evidence for vaccine effectiveness.

We don't currently have agreed tools for evaluating these kinds of studies; it's not always clear how to assess the results, leading to inconsistent interpretations.

Goals

The overall goal of the FEEVA project is to develop consensus tools for assessing evidence for vaccines, beginning with animal models, and moving on to human challenge studies (CHIM), in vitro assays and natural history studies. This will be achieved by convening four Expert Panels, one for each focus area.



Based on a review of evidence, the Expert Panels will propose criteria for assessing each study type, which will be reviewed by a Consultation Panel to produce a framework for evidence evaluation. The project will be overseen by a Steering Committee.



Key Contacts:

Professor Miles Davenport (Kirby Institute)
 Professor Tari Turner (ALEC)

To express your interest or to find out more email FEEVA@kirby.unsw.edu.au